<DOC>
	<DOCNO>NCT02006498</DOCNO>
	<brief_summary>This randomise study examine whether high dose Sillymarin able help improve fat-induced liver damage liver . The study hypothesis high dose Sillymarin able reduce steato-hepatitis ( fat-related liver inflammation ) good placebo .</brief_summary>
	<brief_title>Silymarin Treatment Non-Alcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description>OBJECTIVES OF STUDY Primary Objectives 1 . To assess safety adverse event profile Silymarin compare placebo . 2 . To assess efficacy Silymarin define improvement non-alcoholic steatosis ( NAS ) activity score least 30 % baseline compare placebo . Secondary Objectives 1 . To compare NAS activity Silymarin therapy . 2 . To characterize change ALT AST Silymarin therapy . 3 . To compare insulin resistance measure HOMAr Silymarin therapy .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>Male female 18 year age old . Diagnosed NASH ( refer Section 5.2 ) AST and/or ALT great 40 IU/L . Must agree adhere alcohol consumption guideline . Weight gain//loss 10 % biopsy screen within 30 day screen biopsy perform screening period . No change diabetic and/or lipid medication biopsy screen within 30 day screen biopsy perform screening period Use silymarin milk thistle preparation period 90 consecutive day longer biopsy initial screening , within 30 day prior screen biopsy perform screening period . Use antioxidant nonprescribed complementary alternative medication period 90 consecutive day longer biopsy initial screening , within 30 day prior screen biopsy perform screening period . Use warfarin , metronidazole , acetaminophen ( great 2 gram per day ) screen randomization . Use oral steroid 14 day screen prior randomization . BMI ≥ 35 kg/m2 screen randomization . Poorlycontrolled diabetes ( HbA1c &gt; 8 % ) screen randomization Diabetes mellitus treated oral agent secretagogues metformin screen randomization . Sitagliptin allow . For patient use antihyperlipidemic agent accept antidiabetic agent , change agent dose screen randomization . Radiologic image consistent cirrhosis portal hypertension . Evidence decompensated liver disease Platelet count &lt; 130 x 109 /L screening . History bariatric surgery , undergo evaluation bariatric surgery . Known allergy/sensitivity milk thistle preparation . History immunologically mediate disease History thyroid disease poorly control prescribed medication . History solid organ bone marrow transplantation . Primary hepatic malignancy . Secondary hepatic malignancy extrahepatic malignancy . Serum Creatinine 176 μmol/L great creatinine clearance ( calculate accord CockcroftGault ) 60 mL/min less , dialysis , screen . Severe illness condition would make patient , opinion investigator , unsuitable study . Women ongoing pregnancy breast feeding , contemplate pregnancy . Women childbearing potential practicing acceptable form birth control . Participation research drug trial within 30 day screen . Inability unwillingness give inform consent abide study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>non-alcoholic fatty liver disease</keyword>
	<keyword>sillymarin</keyword>
	<keyword>randomise trial</keyword>
	<keyword>non-alcoholic steatohepatitis</keyword>
</DOC>